Key points are not available for this paper at this time.
Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib. (Funded by Merck Sharp KEYNOTE-426 ClinicalTrials.gov number, NCT02853331.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Rini et al. (Sat,) studied this question.
www.synapsesocial.com/papers/69d7c01a3b601d7be3ae2aed — DOI: https://doi.org/10.1056/nejmoa1816714
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
Brian I. Rini
Elizabeth R. Plimack
V.P. Stus
New England Journal of Medicine
University College London
Cleveland Clinic
Queen Mary University of London
Building similarity graph...
Analyzing shared references across papers
Loading...